title: The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.
abstract: Opioid dependence is largely an undertreated medical condition in the United States. The introduction of buprenorphine has created the potential to expand access to and use of opioid agonist treatment in generalist settings. Physicians, however, often have limited training and experience providing this type of care. Some physicians believe having a mentoring relationship with an experienced provider during their initial introduction to the use of buprenorphine would ease implementation. Our goal was to describe the development, implementation, resources, and evaluation of the Physician Clinical Support System-Buprenorphine (PCSS-B), a federally funded program to improve access to and quality of treatment with buprenorphine. We provide a description of the PCSS-B, a national network of 88 trained physician mentors with expertise in buprenorphine treatment and skills in clinical education. We provide information regarding the use the PCSS-B core services including telephone, email and in-person support, a website, clinical guidances, a warmline and outreach to primary care and specialty organizations. Between July 2005 and July 2009, 67 mentors and 4 clinical experts reported providing mentoring services to 632 participants in 48 states, Washington DC and Puerto Rico. A total of 1,455 contacts were provided through email (45%), telephone (34%) and in-person visits (20%). Seventy-six percent of contacts addressed a clinical issue. Eighteen percent of contacts addressed a logistical issue. The number of contacts per participant ranged from 1-125. Between August 2005 and April 2009 there were 72,822 visits to the PCSS-B website with 179,678 pages viewed. Seven guidances were downloaded more than 1000 times. The warmline averaged more than 100 calls per month. The PCSS-B model provides support for a mentorship program to assist non-specialty physicians in the provision of buprenorphine and may serve as a model for dissemination of other types of care.
authors.affiliation: New York Academy of Medicine, 1216 5th Avenue, New York, NY 10029, USA. jegan@nyam.org
authors.forename: James E
authors.initials: JE
authors.lastname: Egan
authors.forename: Paul
authors.initials: P
authors.lastname: Casadonte
authors.forename: Tracy
authors.initials: T
authors.lastname: Gartenmann
authors.forename: Judith
authors.initials: J
authors.lastname: Martin
authors.forename: Elinore F
authors.initials: EF
authors.lastname: McCance-Katz
authors.forename: Julie
authors.initials: J
authors.lastname: Netherland
authors.forename: John A
authors.initials: JA
authors.lastname: Renner
authors.forename: Linda
authors.initials: L
authors.lastname: Weiss
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Saxon
authors.forename: David A
authors.initials: DA
authors.lastname: Fiellin
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000819:agonists; D002047:Buprenorphine / Q000627:therapeutic use*; D004502:Education, Medical, Continuing / Q000379:methods*; D005240:Feasibility Studies; D006801:Humans; D033181:Information Dissemination / Q000379:methods; D008611:Mentors; D058850:Opiate Substitution Treatment; D010818:Practice Patterns, Physicians'; D019966:Substance-Related Disorders / Q000188:drug therapy*
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine
references.citation: Subst Abus. 2004 Dec;25(4):35-40
references.pmid: 16172091
references.citation: J Subst Abuse Treat. 2004 Sep;27(2):153-9
references.pmid: 15450648
references.citation: Subst Abus. 2006 Sep;27(3):39-45
references.pmid: 17135179
references.citation: Am J Addict. 2004;13 Suppl 1:S67-78
references.pmid: 15204676
references.citation: Am J Med. 1998 Aug;105(2):100-5
references.pmid: 9727815
references.citation: J Addict Med. 2007 Jun;1(2):62-7
references.pmid: 21768936
references.citation: Ann Intern Med. 2000 Jul 4;133(1):40-54
references.pmid: 10877739
references.citation: Fam Pract. 1996 Jun;13(3):264-79
references.pmid: 8671136
references.citation: Clin Infect Dis. 2005 Sep 15;41(6):891-6
references.pmid: 16107991
references.citation: J Subst Abuse Treat. 2009 Apr;36(3):244-51
references.pmid: 18715741
references.citation: JAMA. 2001 Oct 10;286(14):1724-31
references.pmid: 11594897
references.citation: JAMA. 1998 Dec 9;280(22):1936-43
references.pmid: 9851480
references.citation: Am J Med. 1996 Oct;101(4):435-44
references.pmid: 8873515
references.citation: Subst Abus. 2006 Sep;27(3):13-8
references.pmid: 17135176
references.citation: J Subst Abuse Treat. 2006 Jun;30(4):363-73
references.pmid: 16716852
references.citation: Ann Intern Med. 2002 Oct 15;137(8):688-92
references.pmid: 12379070
references.citation: J Gen Intern Med. 1998 Feb;13(2):146
references.pmid: 9502380
references.citation: JAMA. 2001 May 9;285(18):2355-62
references.pmid: 11343483
references.citation: Ann Intern Med. 2001 Nov 20;135(10):889-96
references.pmid: 11712879
references.citation: Int J Nurs Pract. 2007 Dec;13(6):393-6
references.pmid: 18021170
references.citation: J Gen Intern Med. 1994 Mar;9(3):127-30
references.pmid: 8195910
references.citation: J Addict Dis. 2003;22(4):109-20
references.pmid: 14723481
references.citation: Drug Alcohol Depend. 2007 Mar 16;87(2-3):164-74
references.pmid: 16971059
references.citation: Am J Addict. 2004;13 Suppl 1:S8-16
references.pmid: 15204672
references.citation: Fam Med. 2006 May;38(5):336-40
references.pmid: 16673195
references.citation: Med J Aust. 2003 Jul 7;179(1):38-42
references.pmid: 12831383
references.citation: Arch Intern Med. 2005 Aug 8-22;165(15):1769-76
references.pmid: 16087826
references.citation: J Gen Intern Med. 2002 May;17(5):327-33
references.pmid: 12047728